Treatment with recombinant ADAM Metallopeptidase With Thrombospondin Type 1 Motif 13 (ADAMTS13), which cleaves Von Willebrand Factor (VWF) and inhibits its adhesion properties, prevents ascending aortic constriction (AAC)-induced cardiac capillary thrombosis, cardiac fibrosis and improved systolic function (increased EF) (Witsch et al., 2018). The gene discussed is VWF; the disease is deep vein thrombosis.